HER2/Neu GP2 vaccine (Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology)
- Generic Name
- HER2/Neu GP2 vaccine (Greenwich LifeSciences Inc/NuGenerex Immuno-Oncology)
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Greenwich LifeSciences, Inc.
- Target Recruit Count
- 598
- Registration Number
- NCT05232916
- Locations
- 🇺🇸
Arizona Oncology Associates - Tucson, Tucson, Arizona, United States
🇺🇸Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center, Fullerton, California, United States
🇺🇸University of California San Diego - Moores Cancer Center, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath